Congestive heart failure classification

Congestive Heart Failure Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Systolic Dysfunction Diastolic Dysfunction HFpEF HFrEF
Causes
Differentiating Congestive heart failure from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Clinical Assessment
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Cardiac MRI
Echocardiography
Exercise Stress Test
Myocardial Viability Studies
Cardiac Catheterization
Other Imaging Studies
Other Diagnostic Studies
Treatment
Invasive Hemodynamic Monitoring
Medical Therapy:
Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF Diuretics ACE Inhibitors Angiotensin receptor blockers Aldosterone Antagonists Beta Blockers Ca Channel Blockers Nitrates Hydralazine Positive Inotropics Anticoagulants Angiotensin Receptor-Neprilysin Inhibitor Antiarrhythmic Drugs Nutritional Supplements Hormonal Therapies Drugs to Avoid Drug Interactions Treatment of underlying causes Associated conditions
Exercise Training
Surgical Therapy: Biventricular Pacing or Cardiac Resynchronization Therapy (CRT) Implantation of Intracardiac Defibrillator Ultrafiltration Cardiac Surgery Left Ventricular Assist Devices (LVADs) Cardiac Transplantation
ACC/AHA Guideline Recommendations Initial and Serial Evaluation of the HF Patient Hospitalized Patient Patients With a Prior MI Sudden Cardiac Death Prevention Surgical/Percutaneous/Transcather Interventional Treatments of HF Patients at high risk for developing heart failure (Stage A) Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B) Patients with current or prior symptoms of heart failure (Stage C) Patients with refractory end-stage heart failure (Stage D) Coordinating Care for Patients With Chronic HF Quality Metrics/Performance Measures
Implementation of Practice Guidelines
Congestive heart failure end-of-life considerations
Specific Groups: Special Populations Patients who have concomitant disorders Obstructive Sleep Apnea in the Patient with CHF NSTEMI with Heart Failure and Cardiogenic Shock
Congestive heart failure classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Congestive heart failure classification
CDC on Congestive heart failure classification
Congestive heart failure classification in the news
Blogs on Congestive heart failure classification
Directions to Hospitals Treating Congestive heart failure classification
Risk calculators and risk factors for Congestive heart failure classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

There are several classification schemes used to characterize the types of heart failure (systolic or diastolic), to assess the severity (NY Heart Association Class) and the stage congestive heart failure (AHA Class A,B,C,D).

Types of Heart Failure

Patients may be broadly classified as having heart failure with depressed left ventricular ejection fraction (systolic dysfunction) or normal/preserved ejection fraction (diastolic dysfunction). Systolic and diastolic dysfunction commonly occur in conjunction with each other.

Assessing the Severity of Heart Failure: The New York Heart Association Criteria (NYHA)

• NYHA I: No symptoms with ordinary activity.

• NYHA II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.

• NYHA III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.

• NYHA IV: Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency present at rest.

ACC/AHA Classification of Chronic Heart Failure

Classification System based on structural and symptomatic stages of the syndrome.

Introduced to emphasize the natural history of the heart failure syndrome and to identify ealier opportunities to intervene and prevent advancement. (Use along with NYHA starting when symptoms develop (Stages C-D). Stage A: patients at risk of developing heart failure but who have no structural heart disease at present. Stage B: patients with structural heart disease but no symptoms. Stage C: patients with structural heart disease and symptomatic heart failure. Stage D: patients with severe refractory heart failure.

Stage A

Patients “at Risk”

• Hypertension
• Diabetes mellitus
• Coronary artery disease
• Exposure history to cardiac toxins:
• History of cardiotoxic drug therapy.
• History of alcohol abuse.
• Familial history of cardiomyopathy

Stage B

Patients with structural heart disease, but no history of signs or symptoms of heart failure.

• Left ventricular hypertrophy (LVH)
• Myocardial fibrosis
• Left ventricular dilatation or dysfunction
• Asymptomatic valvular heart disease
• Previous myocardial infarction

Stage C

Underlying structural heart disease and symptoms of heart failure.

• Dyspnea or fatigue due to left ventricular systolic dysfunction.
• Asymptomatic patients receiving treatment for prior symptoms of heart failure.

Stage D

Despite of maximal medical therapy, symptoms of heart failure at rest and advanced structural heart disease.

• Being considered for advance options including LVAD and heart transplantation
• Requiring continuous inotropic or mechanical support
• Receiving or being considered for palliative care/end of life care.

Guidelines Resources

• The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult

• 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation